Pub Date : 2020-01-25DOI: 10.3760/CMA.J.ISSN.1009-9921.2020.01.003
Rui-hua Mi, Lin Chen, Xudong Wei
Acute myelogenous leukemia (AML) is a highly heterogeneous malignant hematologic disease, and it is mainly treated with traditional chemotherapy, but the efficacy is limited and the patients with worse performance status and comorbidities can not be treated with chemotherapy. Gene changes play an important role in the diagnosis and prognosis of AML, and these gene changes also provide targets for molecular targeted therapy. Meanwhlie, immunotherapy has achieved certain curative effects in AML and has a promising prospect. In this review, targeted therapy and immunotherapy of AML reported in 61st American Society of Hematology (ASH) Annual Meeting are summarized. Key words: Leukemia, myelogenous, acute; Immunotherapy; Gene change; Molecular targeted therapy
{"title":"New advances in targeted therapy and immunotherapy of acute myelogenous leukemia","authors":"Rui-hua Mi, Lin Chen, Xudong Wei","doi":"10.3760/CMA.J.ISSN.1009-9921.2020.01.003","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2020.01.003","url":null,"abstract":"Acute myelogenous leukemia (AML) is a highly heterogeneous malignant hematologic disease, and it is mainly treated with traditional chemotherapy, but the efficacy is limited and the patients with worse performance status and comorbidities can not be treated with chemotherapy. Gene changes play an important role in the diagnosis and prognosis of AML, and these gene changes also provide targets for molecular targeted therapy. Meanwhlie, immunotherapy has achieved certain curative effects in AML and has a promising prospect. In this review, targeted therapy and immunotherapy of AML reported in 61st American Society of Hematology (ASH) Annual Meeting are summarized. \u0000 \u0000Key words: \u0000Leukemia, myelogenous, acute; Immunotherapy; Gene change; Molecular targeted therapy","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"29 1","pages":"9-16"},"PeriodicalIF":0.0,"publicationDate":"2020-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47042508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Purpose to explore CBF β- Diagnosis and treatment methods for patients with MYH11 fusion gene positive chronic myeloid leukemia (CML) in the acute phase. Method Retrospective analysis of a case of CBF admitted to the First Hospital of Jilin University in December 2015 β- The diagnosis and treatment of CML patients with MYH11 fusion gene positivity during the acute phase, and literature review. As a result, the patient was diagnosed with CML (Acute Myelopathy) and CBF due to fever accompanied by abdominal distension. Physical examination revealed splenomegaly, and blood routine examination, bone marrow biopsy, chromosome and fusion gene screening were performed β- MYH11 positive. After 1.5 months of induction therapy with dasatinib alone, the patient returned to the chronic phase. After 3 months of treatment, haploid hematopoietic stem cell transplantation was performed. As of the end of follow-up (30 months after transplantation), the patient was in a continuous complete remission state. Conclusion with CBF β- MYH11 positive CML patients undergoing acute phase change have fewer adverse reactions and better induction effects when treated with dasatinib alone before transplantation.
{"title":"Dasatinib bridging allogeneic stem cell transplantation in treatment of chronic myeloid leukemia with CBFβ-MYH11 fusion gene-positive in blast phase: report of one case and review of literature","authors":"Rui Wang, Yue Cong, Caili Li, Chen Zhang, Hai Lin","doi":"10.3760/CMA.J.ISSN.1009-9921.2020.01.014","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2020.01.014","url":null,"abstract":"目的 \u0000探讨CBFβ-MYH11融合基因阳性的慢性粒细胞白血病（CML）急变期患者的诊治方法。 \u0000 \u0000 \u0000方法 \u0000回顾性分析吉林大学第一医院2015年12月收治的1例CBFβ-MYH11融合基因阳性的CML急变期患者的诊治经过，并进行文献复习。 \u0000 \u0000 \u0000结果 \u0000该例患者因发热伴腹胀就诊，查体提示脾大，行血常规、骨髓穿刺、染色体及融合基因筛查等，诊断为CML（急髓变）伴CBFβ-MYH11阳性。单用达沙替尼诱导治疗1.5个月后患者回到慢性期，治疗3个月后行单倍体造血干细胞移植，截至随访结束（移植后30个月），患者处于持续完全缓解状态。 \u0000 \u0000 \u0000结论 \u0000伴CBFβ-MYH11阳性的CML急变期患者移植前单用达沙替尼不良反应小且诱导效果较好。","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"29 1","pages":"60-62"},"PeriodicalIF":0.0,"publicationDate":"2020-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47329062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-25DOI: 10.3760/CMA.J.ISSN.1009-9921.2019.12.010
Rui-hua Mi, Lin Chen, H. Ai, F. Yuan, Q. Yin
Objective To analyze the efficacy and safety of lenalidomide combined with interferon (IFN) and interleukin-2 (IL-2) for treatment of refractory/relapsed or minimal residual disease (MRD)-positive acute myelogenous leukemia (AML). Methods Twelve patients with AML who were hospitalized in the Affiliated Cancer Hospital of Zhengzhou University from August 2013 to May 2019 were selected. These patients were previously treated with thalidomide combined with IFN and IL-2, and then treated with combined with IFN and IL-2. According to the Frence-American-British (FAB) classification system, there was 1 case of M0, 1 case of M1, 4 cases of M2a, 3 cases of M2b, 1 case of M4EO, and 2 cases of M5b. There were 2 cases with FLT3-ITD mutation-positive, 1 case with c-kit mutation-positive. There were 2 cases in the low-risk group, 7 cases in the intermediate-risk group, and 3 cases in the high-risk group. Three cases were refractory AML, 7 cases were relapsed AML (including 3 cases of recurrence once, 4 cases of recurrence twice; 5 cases of recent recurrence, 2 cases of long-term recurrence), 2 cases were MRD-positive. The efficacy and adverse reactions of 12 cases were evaluated. Results Twelve patients had received more than one cycle therapy of lenalidomide combined with IFN and IL-2, of which 4 patients achieved morphological complete remission (CR), 2 patients had CR with incomplete recovery of blood cells (CRi), 4 patients had no remission, 1 case had a decrease in MRD, and 1 case had an increase in MRD, and the total effective (CR+ CRi+ partial remission+ MRD decreased) was in 7 cases. There were no adverse reactions such as rash, constipine, bradycardia and peripheral neuritis; six patients had grade Ⅲ or higher experienced myelosuppression. No patients died of complications during the treatment, and the duration of remission of all patients was 2-20 months. Conclusion Lenalidomide combined with IFN and IL-2 for treatment of refractory/relapsed or MRD-positive AML is effective, and it can reduce the MRD value in MRD-positive patients, it could be a new treatment method for AML. Key words: Leukemia, myeloid, acute; Recurrence; Refractory; Minimal residual disease; Interferons; Interleukin-2; Lenalidomide
{"title":"Effect of lenalidomide combined with interferon and interleukin-2 for treatment of refractory/relapsed or minimal residual disease-positive acute myelogenous leukemia","authors":"Rui-hua Mi, Lin Chen, H. Ai, F. Yuan, Q. Yin","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.12.010","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.12.010","url":null,"abstract":"Objective \u0000To analyze the efficacy and safety of lenalidomide combined with interferon (IFN) and interleukin-2 (IL-2) for treatment of refractory/relapsed or minimal residual disease (MRD)-positive acute myelogenous leukemia (AML). \u0000 \u0000 \u0000Methods \u0000Twelve patients with AML who were hospitalized in the Affiliated Cancer Hospital of Zhengzhou University from August 2013 to May 2019 were selected. These patients were previously treated with thalidomide combined with IFN and IL-2, and then treated with combined with IFN and IL-2. According to the Frence-American-British (FAB) classification system, there was 1 case of M0, 1 case of M1, 4 cases of M2a, 3 cases of M2b, 1 case of M4EO, and 2 cases of M5b. There were 2 cases with FLT3-ITD mutation-positive, 1 case with c-kit mutation-positive. There were 2 cases in the low-risk group, 7 cases in the intermediate-risk group, and 3 cases in the high-risk group. Three cases were refractory AML, 7 cases were relapsed AML (including 3 cases of recurrence once, 4 cases of recurrence twice; 5 cases of recent recurrence, 2 cases of long-term recurrence), 2 cases were MRD-positive. The efficacy and adverse reactions of 12 cases were evaluated. \u0000 \u0000 \u0000Results \u0000Twelve patients had received more than one cycle therapy of lenalidomide combined with IFN and IL-2, of which 4 patients achieved morphological complete remission (CR), 2 patients had CR with incomplete recovery of blood cells (CRi), 4 patients had no remission, 1 case had a decrease in MRD, and 1 case had an increase in MRD, and the total effective (CR+ CRi+ partial remission+ MRD decreased) was in 7 cases. There were no adverse reactions such as rash, constipine, bradycardia and peripheral neuritis; six patients had grade Ⅲ or higher experienced myelosuppression. No patients died of complications during the treatment, and the duration of remission of all patients was 2-20 months. \u0000 \u0000 \u0000Conclusion \u0000Lenalidomide combined with IFN and IL-2 for treatment of refractory/relapsed or MRD-positive AML is effective, and it can reduce the MRD value in MRD-positive patients, it could be a new treatment method for AML. \u0000 \u0000 \u0000Key words: \u0000Leukemia, myeloid, acute; Recurrence; Refractory; Minimal residual disease; Interferons; Interleukin-2; Lenalidomide","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"743-748"},"PeriodicalIF":0.0,"publicationDate":"2019-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48872053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Dasatinib monotherapy for chronic myeloid leukemia in blast crisis: report of one case and review of literature","authors":"S. Yao, Y. Lai, Dongbo Ling, Yi‐yao Jiang, Zhangkun Li","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.12.015","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.12.015","url":null,"abstract":"目的 \u0000观察达沙替尼单药治疗慢性粒细胞白血病（CML）急髓变的疗效及安全性。 \u0000 \u0000 \u0000方法 \u0000回顾性分析东莞市人民医院1例应用达沙替尼单药治疗的CML急髓变患者的临床经过，并复习相关文献。 \u0000 \u0000 \u0000结果 \u0000患者骨髓检查提示CML急髓变，同时伴随附加染色体核型异常，但BCR-ABL1激酶区突变阴性，坚持服用达沙替尼（100 mg/d）靶向治疗，并每月动态监测BCR-ABLIS基因水平。患者BCR-ABLIS基因水平逐渐下降，骨髓细胞学提示完全缓解，流式免疫微小残留转阴。治疗期间除可控的骨髓抑制及轻度肝损伤外，未出现其他严重不良反应。 \u0000 \u0000 \u0000结论 \u0000CML急髓变后可根据患者激酶区突变情况选取不同的治疗策略，如无激酶区突变，达沙替尼单药治疗患者易耐受、安全有效，可作为优先治疗方案，但治疗期间需密切监测BCR-ABLIS基因水平，符合移植条件的患者仍应争取异基因造血干细胞移植以改善长期预后。","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"763-765"},"PeriodicalIF":0.0,"publicationDate":"2019-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69842813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-25DOI: 10.3760/CMA.J.ISSN.1009-9921.2019.12.008
Lili Yuan, Huizheng Zhao, Jian-ping Zhang, Fang Wang, Nan Li, Xingzhen Zhao, Xue Chen, Yang Zhang, D. Nie, P. Cao, Mangju Wang, Ming Liu, Mingyue Liu, Hongxing Liu
Objective To investigate the application of metagenomic next-generation sequencing (mNGS) in detection of the rare or difficult-to-cultivate pathogens. Methods One patient with acute lymphoblastic leukemia who went through allogeneic hematopoietic stem cell transplantation (allo-HSCT) developed symptoms of infection after transplantation. Conventional microbial culture, polymerase chain reaction (PCR), and mNGS combined with biological information analysis were performed with plasma and cerebrospinal fluid samples, the anti-infective treatment was adjusted according to the test results, and the efficacy was assessed. Results No suspected pathogens were detected by microbial culture and PCR in the cerebrospinal fluid and plasma samples since the patient developed infection symptoms. However, Legionella pneumophila was analyzed by mNGS in the cerebrospinal fluid specimen on day 23 after allo-HSCT (reads count: 19 655), and it was considered as the principal pathogen after comprehensively evaluating the patient's clinical manifestations and the test results. Then the antimicrobial treatments were adjusted according to the patient's clinical manifestations and laboratory test results, and the number of gene sequences of Legionella pneumophila was monitored by mNGS method. Azithromycin, tigecycline, and other antibiotics effective for Legionella pneumophila were used after detecting this pathogen. A total of 15 mNGS analysis were performed during the 5-month period, and the highest number of Legionella pneumophila sequences monitored in the cerebrospinal fluid was 2 226, the lowest was 253 and eventually turned negative. The clinical symptoms and treatment outcomes were consistent with the mNGS monitoring results. Conclusions The mNGS technology has significant value in detection of the rare and difficult-to-cultivate pathogens. The mNGS technology provides a valuable supplement to microbial culture and PCR methods. Key words: High-throughput nucleotide sequencing; Metagenome; Hematopoietic stem cell transplantation; Legionella pneumophila
{"title":"Application of metagenomics next-generation sequencing in monitoring Legionella pneumophila infection after allogeneic hematopoietic stem cell transplantation","authors":"Lili Yuan, Huizheng Zhao, Jian-ping Zhang, Fang Wang, Nan Li, Xingzhen Zhao, Xue Chen, Yang Zhang, D. Nie, P. Cao, Mangju Wang, Ming Liu, Mingyue Liu, Hongxing Liu","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.12.008","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.12.008","url":null,"abstract":"Objective \u0000To investigate the application of metagenomic next-generation sequencing (mNGS) in detection of the rare or difficult-to-cultivate pathogens. \u0000 \u0000 \u0000Methods \u0000One patient with acute lymphoblastic leukemia who went through allogeneic hematopoietic stem cell transplantation (allo-HSCT) developed symptoms of infection after transplantation. Conventional microbial culture, polymerase chain reaction (PCR), and mNGS combined with biological information analysis were performed with plasma and cerebrospinal fluid samples, the anti-infective treatment was adjusted according to the test results, and the efficacy was assessed. \u0000 \u0000 \u0000Results \u0000No suspected pathogens were detected by microbial culture and PCR in the cerebrospinal fluid and plasma samples since the patient developed infection symptoms. However, Legionella pneumophila was analyzed by mNGS in the cerebrospinal fluid specimen on day 23 after allo-HSCT (reads count: 19 655), and it was considered as the principal pathogen after comprehensively evaluating the patient's clinical manifestations and the test results. Then the antimicrobial treatments were adjusted according to the patient's clinical manifestations and laboratory test results, and the number of gene sequences of Legionella pneumophila was monitored by mNGS method. Azithromycin, tigecycline, and other antibiotics effective for Legionella pneumophila were used after detecting this pathogen. A total of 15 mNGS analysis were performed during the 5-month period, and the highest number of Legionella pneumophila sequences monitored in the cerebrospinal fluid was 2 226, the lowest was 253 and eventually turned negative. The clinical symptoms and treatment outcomes were consistent with the mNGS monitoring results. \u0000 \u0000 \u0000Conclusions \u0000The mNGS technology has significant value in detection of the rare and difficult-to-cultivate pathogens. The mNGS technology provides a valuable supplement to microbial culture and PCR methods. \u0000 \u0000 \u0000Key words: \u0000High-throughput nucleotide sequencing; Metagenome; Hematopoietic stem cell transplantation; Legionella pneumophila","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"734-738"},"PeriodicalIF":0.0,"publicationDate":"2019-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44700690","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-25DOI: 10.3760/CMA.J.ISSN.1009-9921.2019.12.007
Chun-Xia Cai, Jian Li, S. Le, Hao Zheng, X. Hua, Zaisheng Chen, Yongzhi Zheng
Objective To investigate the clinical effect and safety of dasatinib combined with Chinese Children's Leukemia Group-acute lymphoblastic leukemia (CCLG-ALL) 2008 protocol in treatment of childhood Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Methods The clinical data of 22 patients with Ph+ ALL who were newly diagnosed at the age of less than 15 years old in Fujian Medical University Union Hospital from January 2014 to December 2018 were retrospectively analyzed. All patients were treated with dasatinib combined with CCLG-ALL2008 protocol (high-risk group). The patients were assigned to two groups according to different starting times of oral dasatinib: the dasatinib-induced group (starting from day 15 of induction chemotherapy) and the dasatinib-consolidated group (starting with early consolidated chemotherapy). The early treatment response and 5-year event-free survival (EFS) rate were compared between the two groups. Results The differences of clinical characteristics and early efficacy of chemotherapy before treatment of dasatinib between the two groups were not statistically significant (both P > 0.05). The complete remission (CR) rate on day 33 of induction chemotherapy was higher in the dasatinib-induced group than that in the dasatinib-consolidated group [100% (10/10) vs. 75% (9/12)], but the difference was not statistically significant (χ 2= 2.895, P= 0.221). The rate of minimal residual disease (MRD) turned negative ( 0.05). Conclusions Dasatinib combined with CCLG-ALL2008 protocol in the treatment of children with Ph+ ALL has good efficacy and safety. Furthermore, the early use of dasatinib on day 15 of induction chemotherapy can enable patients to achieve deeper remission earlier and improve long-term efficacy. Key words: Leukemia, lymphocytic, acute; Philadelphia chromosome; Child; Dasatinib; Molecular targeted therapy
{"title":"Clinical effect and safety of dasatinib combined with Chinese Children's Leukemia Group-acute lymphoblastic leukemia 2008 protocol in treatment of childhood Philadelphia chromosome-positive acute lymphoblastic leukemia","authors":"Chun-Xia Cai, Jian Li, S. Le, Hao Zheng, X. Hua, Zaisheng Chen, Yongzhi Zheng","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.12.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.12.007","url":null,"abstract":"Objective \u0000To investigate the clinical effect and safety of dasatinib combined with Chinese Children's Leukemia Group-acute lymphoblastic leukemia (CCLG-ALL) 2008 protocol in treatment of childhood Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). \u0000 \u0000 \u0000Methods \u0000The clinical data of 22 patients with Ph+ ALL who were newly diagnosed at the age of less than 15 years old in Fujian Medical University Union Hospital from January 2014 to December 2018 were retrospectively analyzed. All patients were treated with dasatinib combined with CCLG-ALL2008 protocol (high-risk group). The patients were assigned to two groups according to different starting times of oral dasatinib: the dasatinib-induced group (starting from day 15 of induction chemotherapy) and the dasatinib-consolidated group (starting with early consolidated chemotherapy). The early treatment response and 5-year event-free survival (EFS) rate were compared between the two groups. \u0000 \u0000 \u0000Results \u0000The differences of clinical characteristics and early efficacy of chemotherapy before treatment of dasatinib between the two groups were not statistically significant (both P > 0.05). The complete remission (CR) rate on day 33 of induction chemotherapy was higher in the dasatinib-induced group than that in the dasatinib-consolidated group [100% (10/10) vs. 75% (9/12)], but the difference was not statistically significant (χ 2= 2.895, P= 0.221). The rate of minimal residual disease (MRD) turned negative ( 0.05). \u0000 \u0000 \u0000Conclusions \u0000Dasatinib combined with CCLG-ALL2008 protocol in the treatment of children with Ph+ ALL has good efficacy and safety. Furthermore, the early use of dasatinib on day 15 of induction chemotherapy can enable patients to achieve deeper remission earlier and improve long-term efficacy. \u0000 \u0000 \u0000Key words: \u0000Leukemia, lymphocytic, acute; Philadelphia chromosome; Child; Dasatinib; Molecular targeted therapy","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"728-733"},"PeriodicalIF":0.0,"publicationDate":"2019-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48489710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective To improve the understanding of breast cancer with diffuse large B-cell lymphoma (DLBCL) in the stomach. Methods A case of breast cancer complicated with gastric DLBCL in Lanzhou General Hospital of Lanzhou Military Region was analyzed in terms of etiology, clinical manifestations, immunohistochemistry, pathological characteristics, and literature review. Results After the elderly breast cancer patient was diagnosed and treated with endocrine therapy for more than 3 years, he suffered from gastric DLBCL again, and the non germinal center B cell subtype IGH was positive. Conclusion After the treatment of breast cancer patients, the incidence of lymphoma increases, and clinicians need to be vigilant.
{"title":"Breast cancer combined with diffuse large B-cell lymphoma of the stomach: report of one case and review of literature","authors":"Jing Wang, Tao Wu, Ying Han, F. Xue, Yaozhu Pan, Cun-bang Wang","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.12.014","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.12.014","url":null,"abstract":"目的 \u0000提高对乳腺癌合并胃弥漫大B细胞淋巴瘤（DLBCL）的认识。 \u0000 \u0000 \u0000方法 \u0000对兰州军区兰州总医院1例乳腺癌合并胃DLBCL患者的病因、临床表现、免疫组织化学、病理特征等进行分析，并文献相关复习。 \u0000 \u0000 \u0000结果 \u0000该例高龄乳腺癌患者确诊后，行内分泌治疗3年余，再次患胃DLBCL，非生发中心B细胞亚型IGH阳性。 \u0000 \u0000 \u0000结论 \u0000乳腺癌患者治疗后，淋巴瘤的发生概率增加，需要临床医生提高警惕。","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"761-763"},"PeriodicalIF":0.0,"publicationDate":"2019-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48536649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-25DOI: 10.3760/CMA.J.ISSN.1009-9921.2019.12.001
Hongxing Liu, Xue Chen, F. Wang, Xiaoli Ma, Lili Yuan, P. Cao, D. Nie
Transcriptome sequencing (RNA-seq) has unique advantages in analyzing gene fusion, splicing mutations, and gene expression profiles. Single-cell RNA-seq provides powerful tools to reveal cellular heterogeneity in normal and tumor tissues. With the widespread application of high-throughput gene sequencing technology and the rapid reduction in cost, RNA-seq is increasingly used in hematological malignancies research. This article introduces the related research progress in conjunction with reports at the 61st American Society of Hematology Annual Meeting. Key words: High-throughput nucleotide sequencing; Transcriptome; Gene sequencing; Fusion genes; Gene mutations; Hematological malignancies
{"title":"Application progress of transcriptome sequencing in hematological malignancies","authors":"Hongxing Liu, Xue Chen, F. Wang, Xiaoli Ma, Lili Yuan, P. Cao, D. Nie","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.12.001","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.12.001","url":null,"abstract":"Transcriptome sequencing (RNA-seq) has unique advantages in analyzing gene fusion, splicing mutations, and gene expression profiles. Single-cell RNA-seq provides powerful tools to reveal cellular heterogeneity in normal and tumor tissues. With the widespread application of high-throughput gene sequencing technology and the rapid reduction in cost, RNA-seq is increasingly used in hematological malignancies research. This article introduces the related research progress in conjunction with reports at the 61st American Society of Hematology Annual Meeting. \u0000 \u0000 \u0000Key words: \u0000High-throughput nucleotide sequencing; Transcriptome; Gene sequencing; Fusion genes; Gene mutations; Hematological malignancies","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"705-708"},"PeriodicalIF":0.0,"publicationDate":"2019-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48503368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-25DOI: 10.3760/CMA.J.ISSN.1009-9921.2019.12.006
Yi-Min Ren
Mantle cell lymphoma (MCL) is a subtype of aggressive B-cell non-Hodgkin lymphoma(NHL) with a heterogeneous clinical characteristics, accounting for 3%-10% of adult-onset NHL. With the great advance of novel drugs, the therapeutic options for MCL are constantly updating. The 61st American Society of Hematology Annual Meeting reported the recent treatment progress of MCL including novel drugs,combinations of nonchemotherapeutic agents and chimeric antigen receptor T-cell therapy. This paper focuses on the treatment progress of MCL. Key words: Lymphoma, mantle-cell; Lymphoma, non-Hodgkin; Molecular targeted therapy; Immunotherapy; Chimeric antigen receptor T cell
{"title":"Treatment progress of mantle cell lymphoma","authors":"Yi-Min Ren","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.12.006","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.12.006","url":null,"abstract":"Mantle cell lymphoma (MCL) is a subtype of aggressive B-cell non-Hodgkin lymphoma(NHL) with a heterogeneous clinical characteristics, accounting for 3%-10% of adult-onset NHL. With the great advance of novel drugs, the therapeutic options for MCL are constantly updating. The 61st American Society of Hematology Annual Meeting reported the recent treatment progress of MCL including novel drugs,combinations of nonchemotherapeutic agents and chimeric antigen receptor T-cell therapy. This paper focuses on the treatment progress of MCL. \u0000 \u0000 \u0000Key words: \u0000Lymphoma, mantle-cell; Lymphoma, non-Hodgkin; Molecular targeted therapy; Immunotherapy; Chimeric antigen receptor T cell","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"724-727"},"PeriodicalIF":0.0,"publicationDate":"2019-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42698508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2019-12-25DOI: 10.3760/CMA.J.ISSN.1009-9921.2019.12.009
Momei Zhou, Y. Shao, Xueyun Shan, Chunbin Wang, P. Wang
Objective To evaluate the efficacy and side effects of priming regimen with pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in the treatment of initial treatment elderly patients with acute myeloid leukemia (AML). Methods Thirty-five elderly patients with early-stage AML (non-M3) who received pre-excitation chemotherapy in Yancheng Third People's Hospital from February 2015 to January 2019 were retrospectively analyzed. According to the different granulocyte colony-stimulating factor (G-CSF) in the chemotherapy regimen, 15 cases were in PEG-rhG-CSF group, 6 mg PEG-rhG-CSF was used alone on day 0 by subcutaneous injection; 20 cases were in recombinant human granulocyte colony-stimulating factor (rhG-CSF) group, 200 μg/m2 rhG-CSF was used per day from day 0 to day 13 by subcutaneous injection, rhG-CSF was suspended or continued according to the number of white blood cells. In addition, both groups were given priming regimen with cytarabine and arubicin, or cytarabine and harringtonine. The efficacy and adverse reactions of the two groups were compared. Results In the PEG-rhG-CSF group, there were 5 cases of complete remission, 6 cases of partial remission, 4 cases of non-remission, and 11 cases were effective. In the rhG-CSF group, there were 8 cases of complete remission, 7 cases of partial remission, 5 cases of non-remission, and 15 cases were effective. There was no significant difference in the efficacy between the two groups (χ 2= 0.012, P= 0.911). In terms of adverse reactions, the incidence of infectious fever, bone pain, duration of neutropenia, and duration of thrombocytopenia were not statistically significant (all P > 0.05). Conclusions In the pre-excitation chemotherapy for AML, the clinical efficacy and adverse effects of PEG-rhG-CSF are similar to rhG-CSF. However, the use of PEG-rhG-CSF can simplify the operation and reduce the pain and risk of local infection during chemotherapy. Key words: Leukemia, myeloid, acute; Polyethylene glycols; Granulocyte colony-stimulating factor; Priming regimen
{"title":"Clinical observation of priming regimen with pegylated recombinant human granulocyte colony-stimulating factor for treatment of initial treatment elderly patients with acute myeloid leukemia","authors":"Momei Zhou, Y. Shao, Xueyun Shan, Chunbin Wang, P. Wang","doi":"10.3760/CMA.J.ISSN.1009-9921.2019.12.009","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1009-9921.2019.12.009","url":null,"abstract":"Objective \u0000To evaluate the efficacy and side effects of priming regimen with pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) in the treatment of initial treatment elderly patients with acute myeloid leukemia (AML). \u0000 \u0000 \u0000Methods \u0000Thirty-five elderly patients with early-stage AML (non-M3) who received pre-excitation chemotherapy in Yancheng Third People's Hospital from February 2015 to January 2019 were retrospectively analyzed. According to the different granulocyte colony-stimulating factor (G-CSF) in the chemotherapy regimen, 15 cases were in PEG-rhG-CSF group, 6 mg PEG-rhG-CSF was used alone on day 0 by subcutaneous injection; 20 cases were in recombinant human granulocyte colony-stimulating factor (rhG-CSF) group, 200 μg/m2 rhG-CSF was used per day from day 0 to day 13 by subcutaneous injection, rhG-CSF was suspended or continued according to the number of white blood cells. In addition, both groups were given priming regimen with cytarabine and arubicin, or cytarabine and harringtonine. The efficacy and adverse reactions of the two groups were compared. \u0000 \u0000 \u0000Results \u0000In the PEG-rhG-CSF group, there were 5 cases of complete remission, 6 cases of partial remission, 4 cases of non-remission, and 11 cases were effective. In the rhG-CSF group, there were 8 cases of complete remission, 7 cases of partial remission, 5 cases of non-remission, and 15 cases were effective. There was no significant difference in the efficacy between the two groups (χ 2= 0.012, P= 0.911). In terms of adverse reactions, the incidence of infectious fever, bone pain, duration of neutropenia, and duration of thrombocytopenia were not statistically significant (all P > 0.05). \u0000 \u0000 \u0000Conclusions \u0000In the pre-excitation chemotherapy for AML, the clinical efficacy and adverse effects of PEG-rhG-CSF are similar to rhG-CSF. However, the use of PEG-rhG-CSF can simplify the operation and reduce the pain and risk of local infection during chemotherapy. \u0000 \u0000 \u0000Key words: \u0000Leukemia, myeloid, acute; Polyethylene glycols; Granulocyte colony-stimulating factor; Priming regimen","PeriodicalId":16246,"journal":{"name":"Journal of Leukemia and Lymphoma","volume":"28 1","pages":"739-742"},"PeriodicalIF":0.0,"publicationDate":"2019-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42216353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：